Polymorphisms in or near tumour necrosis factor (TNF)-gene do not determine levels of endotoxin-induced TNF production

Genes and Immunity

Volumn 3, Issue 1, 2002, Pages 25-29

  de Jong, B A ^a   Westendorp, R G J ^a   Bakker, A M ^a   Huizinga, T W J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Immunogenetics; Polymerase chain reaction; Polymorphisms; Production; TNF

Indexed keywords

ENDOTOXIN; TUMOR NECROSIS FACTOR; HLA DR ANTIGEN; MICROSATELLITE DNA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD CULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DATA ANALYSIS; DNA POLYMORPHISM; FEMALE; GENETIC IDENTIFICATION; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE MARKER; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; BIOSYNTHESIS; COMPARATIVE STUDY; GENETIC POLYMORPHISM; GENETICS; HAPLOTYPE; MIDDLE AGED; NETHERLANDS; NUCLEOTIDE SEQUENCE;

ADULT; BASE SEQUENCE; ENDOTOXINS; FEMALE; HAPLOTYPES; HETEROZYGOTE; HLA-DR ANTIGENS; HUMANS; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; NETHERLANDS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036480308     PISSN: 14664879     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gene.6363824     Document Type: Article

References (41)

1. Beutler BA. The role of tumor necrosis factor in health and disease. J Rheumatol 1999; 26 (Suppl 57): 16-21.
2. Tracey KJ, Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med 1994; 45: 491-503.
3. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992; 10: 411-452.
4. Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-1035.
5. Maini RN, Taylor PC, Paleolog E et al. Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis. Ann Rheum Dis 1999; 58 (Suppl 1): I56-I60.
6. The MHC sequencing consortium. Complete sequence and gene map of a human major histocompatibility complex. The MHC sequencing consortium. Nature 1999; 40: 921-923.
7. Pociot F, Briant L, Jongeneel CV et al. Association of tumor necrosis factor (TNF) and class II major histocompatibility complex alleles with the secretion of TNF-alpha and TNF-beta by human mononuclear cells: a possible link to insulin- dependent diabetes mellitus. Eur J Immunol 1993; 23: 224-231.
8. Wilson AG, di Giovine FS, Blakemore AI, Duff GW. Single base polymorphism in the human tumour necrosis factor alpha (TNF alpha) gene detectable by NcoI restriction of PCR product. Hum Mol Genet 1992; 1: 353.
9. D'Alfonso S, Richiardi PM. An intragenic polymorphism in the human tumor necrosis factor alpha (TNFA) chain-encoding gene. Immunogenetics 1996; 44: 321-322.
10. Zimmerman PA, Guderian RH, Nutman TB. A new TNFA promoter allele identified in South American Blacks. Immunogenetics 1996; 44: 485-486.
11. D'Alfonso S, Richiardi PM. A polymorphic variation in a putative regulation box of the TNFA promoter region. Immunogenetics 1994; 39: 150-154.
12. Higuchi T, Seki N, Kamizono S et al. Polymorphism of the 5′-flanking region of the human tumor necrosis factor (TNF)-alpha gene in Japanese. Tissue Antigens 1998; 51: 605-612.
13. Brinkman BM, Giphart MJ, Verhoef A et al. Tumor necrosis factor alpha-308 gene variants in relation to major histocompatibility complex alleles and Felty's syndrome. Hum Immunol 1994; 41: 259-266.
14. Hamann A, Mantzoros C, Vidal-Puig A, Flier JS. Genetic variability in the TNF-alpha promoter is not associated with type II diabetes mellitus (NIDDM). Biochem Biophys Res Commun 1995; 211: 833-839.
15. Allen RD. Polymorphism of the human TNF-alpha promoter-random variation or functional diversity? Mol Immunol 1999; 36: 1017-1027.
16. Uglialoro AM, Turbay D, Pesavento PA et al. Identification of three new single nucleotide polymorphisms in the human tumor necrosis factor-alpha gene promoter. Tissue Antigens 1998; 52: 359-367.
17. Brinkman BM, Kaijzel EL, Huizinga TW, Giphart MJ, Breedveld FC, Verweij CL. Detection of a C-insertion polymorphism within the human tumor necrosis factor alpha (TNFA) gene. Hum Genet 1995; 96: 493.
18. de Jong BA, Schrijver HM, Huizinga TW et al. Innate production of IL-10 and TNF affects the risk multiple sclerosis. Ann Neurol 2000; 48: 641-646.
19. Sandberg-Wollheim M, Ciusani E, Salmaggi A, Pociot F. An evaluation of tumor necrosis factor microsatellite alleles in genetic susceptibility to multiple sclerosis. Mult Scler 1995; 1: 181-185.
20. de Jong BA, Huizinga TW, Zanelli E et al. Evidence for additional genetic risk indicators of relapse-onset multiple sclerosis within the human leukocyte antigen (HLA)- region (submitted for publication).
21. Fernandez-Arquero M, Arroyo R, Rubio A et al. Primary association of a TNF gene polymorphism with susceptibility to multiple sclerosis. Neurology 1999; 53: 1361-1363.
22. Huizinga TW, Westendorp RG, Bollen EL et al. TNF-alpha promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients. J Neuroimmunol 1997; 72: 149-153.
23. Roth MP, Nogueira L, Coppin H et al. Tumor necrosis factor polymorphism in multiple sclerosis: no additional association independent of HLA. J Neuroimmunol 1994; 51: 93-99.
24. Lucotte G, Bathelier C, Mercier G. TNF-alpha polymorphisms in multiple sclerosis: no association with -238 and -308 promoter alleles, but the microsatellite allele all is associated with the disease in French patients. Mult Scler 2000; 6: 78-80.
25. Braun N, Michel U, Ernst BP et al. Gene polymorphism at position -308 of the tumor-necrosis-factor-alpha (TNF-alpha) in multiple sclerosis and it's influence on the regulation of TNF-alpha production. Neurosci Lett 1996; 215: 75-78.
26. Mycko M, Kowalski W, Kwinkowski M et al. Multiple sclerosis: the frequency of allelic forms of tumor necrosis factor and lymphotoxin-alpha. J Neuroimmunol 1998; 84: 198-206.
27. Wingerchuk D, Liu Q, Sobell J et al. A population based case control study of the tumor necrosis factor-alpha-308 polymorphism in multiple sclerosis. Neurology 1997; 49: 626-628.
28. Jacob CO, Fronek Z, Lewis GD, Koo M, Hansen JA, McDevitt HO. Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci USA 1990; 87: 1233-1237.
29. Westendorp RG, Langermans JA, Huizinga TW et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet 1997; 349: 170-173.
30. van der Linden MW, Huizinga TW, Stoeken DJ, Sturk A, Westendorp RG. Determination of tumour necrosis factor-alpha and interleukin-10 production in a whole blood stimulation system: assessment of laboratory error and individual variation. J Immunol Methods 1998; 218: 63-71.
31. Brinkman BM, Zuijdeest D, Kaijzel EL, Breedveld FC, Verweij CL. Relevance of the tumor necrosis factor alpha (TNF alpha) -308 promoter polymorphism in TNF alpha gene regulation. J Inflamm 1995; 46: 32-41.
32. Rood MJ, van Krugten MV, Zanelli E et al. TNF-308A and HLA-DR3 alleles contribute independently to susceptibility to systemic lupus erythematosus. Arthritis Rheum 2000; 43: 129-134.
33. Zipp F, Weber F, Huber S et al. Genetic control of multiple sclerosis: increased production of lymphotoxin and tumor necrosis factor-alpha by HLA-DR2+ T cells. Ann Neurol 1995; 38: 723-730.
34. Peces R, Urra JM, de la Torre M. Influence of HLA-DR phenotype on tumor necrosis factor-alpha production in renal-transplant recipients. Nephron 1995; 71: 180-183.
35. van der Linden MW, Westendorp RG, Sturk A, Bergman W, Huizinga TW. High interleukin-10 production in first-degree relatives of patients with generalized but not cutaneous lupus erythematosus. J Investig Med 2000; 48: 327-334.
36. Jongeneel CV, Briant L, Udalova IA, Sevin A, Nedospasov SA, Cambon-Thomsen A. Extensive genetic polymorphism in the human tumor necrosis factor region and relation to extended HLA haplotypes. Proc Natl Acad Sci USA 1991; 88: 9717-9721.
37. Foissac A, Cambon-Thomsen A. Microsatellites in the HLA region: 1998 update. Tissue Antigens 1998; 52: 318-352.
38. Maniatis T, Fritsch EF, Sambrook J. Molecular Cloning: A Laboratory Manual. Cold Springer Harbor Laboratory, 1982.
39. Degli-Esposti MA, Griffiths MS, Daly LN et al. Characterization of 4AOHW cell line panel including new data for the 10IHW panel. Hum Immunol 1993; 38: 3-16.
40. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992; 39: 225-235.
41. Verduyn W, Doxiadis II, Anholts J et al. Biotinylated DRB sequence-specific oligonucleotides. Comparison to serologic HLA-DR typing of organ donors in eurotransplant. Hum Immunol 1993; 37: 59-67.